Results 101 to 110 of about 3,430 (196)

Subgroup analysis for accuracy of PLA2R-AB for MN detection.

open access: yes, 2014
Subgroup analysis for accuracy of PLA2R-AB for MN detection.
Junhua Li (125998)   +8 more
core   +1 more source

Serum anti-PLA2R negativity does not exclude glomerular PLA2R expression in primary membranous nephropathy

open access: yesBiomolecules & Biomedicine
Primary membranous nephropathy (pMN) is a principal cause of nephrotic syndrome in adults. The identification of the M-type phospholipase A2 receptor (PLA2R) antigen has significantly advanced non-invasive management; however, the precise clinical ...
Şenay Yıldırım   +5 more
doaj   +1 more source

Comportamiento de PLA2R y anti PLA2R en Nefropatía Membranosa Idiopática, pronóstico y respuesta a tratamiento con anti CD20 [PDF]

open access: yes
INTRODUCCIÓN: La Nefropatía Membranosa Idiopática (NMI) es una enfermedad autoinmune que puede ocasionar Síndrome Nefrótico por la formación de inmunocomplejos, se ha identificado el Receptor Fosfolipasa A2 tipo M (PLA2R) como autoantígeno involucrado ...
Carrasco Pardo, Kattia Giovanna   +1 more
core  

Examples of positive and negative staining for THSD7A, PLA2R, and IgG4.

open access: yes, 2015
Positive staining for THSD7A (a, b), PLA2R (e, f), and IgG4 (i, j), and negative staining for THSD7A (c, d), PLA2R (g, h), and IgG4 (k, l) are shown.
Hideo Yasuda (710367)   +4 more
core   +1 more source

Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study.

open access: yesPLoS ONE
BackgroundM-type phospholipase A2 receptor (PLA2R) is a major auto-antigen of primary membranous nephropathy(PMN). Anti-PLA2R antibody levels are closely associated with disease severity and therapeutic effectiveness.
Kezhi Zhou   +13 more
doaj   +1 more source

Study on predictors for treatment efficacy of rituximab in patients with PLA2R-negative primary membranous nephropathy

open access: yes
Objective To evaluate the clinical efficacy of rituximab (RTX) in patients with phospholipase A2 receptor (PLA2R)-negative primary membranous nephropathy (PMN) presenting as nephrotic syndrome, and to identify predictors for treatment efficacy.
XU Lili, HU Xiaofan, LI Hao, WANG Weiming
core   +1 more source

Designing Clinical Trials for the Treatment of Membranous Nephropathy in the Anti-Phospholipase A2 Receptor 1 Era: Results of a NephCure Membranous Nephropathy Workshop

open access: yesGlomerular Diseases
Primary membranous nephropathy is a common cause of adult-onset nephrotic syndrome, with an overall incidence of 12 cases per million per year.
Marco Prunotto   +8 more
doaj   +1 more source

PLA2R and membranous nephropathy: A 3 year prospective Australian study

open access: yes, 2016
PLA2R and membranous nephropathy: A 3 year prospective Australian ...
PA Hill (14541284)   +2 more
core  

Advances in the pathogenesis and clinical applications of PLA2R-associated membranous nephropathy

open access: yes
Membranous nephropathy is one of the main pathological types of nephrotic syndrome. PLA2R(phospholipase A2 receptor)associated membranous nephropathy is the predominant type of primary membranous nephropathy, also known as idiopathic membranous ...
Sun Miao-xin   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy